Individual differences |
Methods | Statistics | Clinical | Educational | Industrial | Professional items | World psychology |
Parkinson's disease or PD (also known as Parkinson's syndrome or paralysis agitans ) is a neurodegenerative disorder of the central nervous system that often impairs the sufferer's motor skills, speech, and other functions.
Parkinson's disease belongs to a group of conditions called movement disorders. It is characterized by muscle rigidity, tremor, a slowing of physical movement (bradykinesia) and, in extreme cases, a loss of physical movement (akinesia). The primary symptoms are the results of decreased stimulation of the motor cortex by the basal ganglia, normally caused by the insufficient formation and action of dopamine, which is produced in the dopaminergic neurons of the brain. Secondary symptoms may include high level cognitive dysfunction and subtle language problems. PD is both chronic and progressive.
PD is the most common cause of chronic progressive parkinsonism, a term which refers to the syndrome of tremor, rigidity, bradykinesia and postural instability. PD is also called "primary parkinsonism" or "idiopathic PD" (classically meaning having no known cause although this term is not strictly true in light of the plethora of newly discovered genetic mutations). While many forms of parkinsonism are "idiopathic", "secondary" cases may result from toxicity most notably of drugs, head trauma, or other medical disorders. The disease is named after English physician James Parkinson, who made a detailed description of the disease in his essay: "An Essay on the Shaking Palsy" (1817).
"Parkinson's disease" is the synonym of "primary parkinsonism", i.e. isolated parkinsonism due to a neurodegenerative process without any secondary systemic cause. In some cases, it would be inaccurate to say that the cause is "unknown", because a small proportion is caused by genetic mutations. It is possible for a patient to be initially diagnosed with Parkinson's disease but then to develop additional features, requiring revision of the diagnosis.
There are other disorders that are called Parkinson-plus diseases. These include: multiple system atrophy (MSA), progressive supranuclear palsy (PSP) and corticobasal degeneration (CBD). Some include dementia with Lewy bodies (DLB) — while idiopathic Parkinson's disease patients also have Lewy bodies in their brain tissue, the distribution is denser and more widespread in DLB. Even so, the relationship between Parkinson disease, Parkinson disease with dementia (PDD), and dementia with Lewy bodies (DLB) might be most accurately conceptualized as a spectrum, with a discrete area of overlap between each of the three disorders. The natural history and role of Lewy bodies is little understood.
These Parkinson-plus diseases may progress more quickly than typical idiopathic Parkinson disease. If cognitive dysfunction occurs before or very early in the course of the movement disorder then DLBD may be suspected. Early postural instability with minimal tremor especially in the context of ophthalmoparesis should suggest PSP. Early autonomic dysfunction including erectile dysfunction and syncope may suggest MSA. The presence of extreme asymmetry with patchy cortical cognitive defects such as dysphasia and apraxias especially with "alien limb" phenomena should suggest CBD.
The usual anti-Parkinson's medications are typically either less effective or not effective at all in controlling symptoms; patients may be exquisitely sensitive to neuroleptic medications like haloperidol. Additionally, the cholinesterase inhibiting medications have shown preliminary efficacy in treating the cognitive, psychiatric, and behavioral aspects of the disease, so correct differential diagnosis is important.
Essential tremor may be mistaken for Parkinson's disease but lacks all other features besides tremor, and has particular characteristics distinguishing it from Parkinson's, such as improvement with beta blockers and alcoholic beverages.
Wilson's disease (hereditary copper accumulation) may present with parkinsonian features; young patients presenting with parkinsonism or any other movement disorder are frequently screened for this rare condition, because it may respond to medical treatment. Typical tests are liver function, slit lamp examination for Kayser-Fleischer rings, and serum ceruloplasmin levels.
Signs and symptoms
Parkinson disease affects movement (motor symptoms). Other typical symptoms include disorders of mood, behaviour, thinking, and sensation (non-motor symptoms). Patients' individual symptoms may be quite dissimilar and progression of the disease is also distinctly individual.
- Tremor: normally 4-6 Hz tremor, maximal when the limb is at rest, and decreased with voluntary movement. It is typically unilateral at onset. This is the most apparent and well-known symptom, though an estimated 30% of patients have little perceptible tremor; these are classified as akinetic-rigid.
- Rigidity: stiffness; increased muscle tone. In combination with a resting tremor, this produces a ratchety, "cogwheel" rigidity when the limb is passively moved.
- bradykinesia/Akinesia: respectively, slowness or absence of movement. Rapid, repetitive movements produce a dysrhythmic and decremental loss of amplitude.
- Postural instability: failure of postural reflexes, which leads to impaired balance and falls.
Other motor symptoms include:
- Gait and posture disturbances:
- Shuffling: gait is characterized by short steps, with feet barely leaving the ground, producing an audible shuffling noise. Small obstacles tend to cause the patient to trip.
- Decreased arm-swing.
- Turning "en bloc": rather than the usual twisting of the neck and trunk and pivoting on the toes, PD patients keep their neck and trunk rigid, requiring multiple small steps to accomplish a turn.
- Stooped, forward-flexed posture. In severe forms, the head and upper shoulders may be bent at a right angle relative to the trunk (camptocormia). 
- Festination: a combination of stooped posture, imbalance, and short steps. It leads to a gait that gets progressively faster and faster, often ending in a fall.
- Gait freezing: "freezing" is a manifestation of akinesia (an inability to move). Gait freezing is characterized by an inability to move the feet which may worsen in tight, cluttered spaces or when attempting to initiate gait.
- Dystonia (in about 20% of cases): abnormal, sustained, painful twisting muscle contractions, often affecting the foot and ankle (mainly toe flexion and foot inversion) which often interferes with gait.
- Speech and swallowing disturbances.
- Hypophonia: soft speech. Speech quality tends to be soft, hoarse, and monotonous. Some people with Parkinson's disease claim that their tongue is "heavy" or have cluttered speech.
- Monotonic speech.
- Festinating speech: excessively rapid, soft, poorly-intelligible speech.
- Drooling: most likely caused by a weak, infrequent swallow and stooped posture.
- Dysphagia: impaired ability to swallow. Can lead to aspiration, pneumonia.
- Other motor symptoms:
- Fatigue (up to 50% of cases);
- Masked faces (a mask-like face also known as hypomimia), with infrequent blinking;
- Difficulty rolling in bed or rising from a seated position;
- Micrographia (small, cramped handwriting);
- Impaired fine motor dexterity and motor coordination;
- Impaired gross motor coordination;
- Akathisia, the inability to sit still.
PD causes cognitive and mood disturbances, being in many cases related.
Estimated prevalence rates of depression vary widely according to the population sampled and methodology used. Reviews of depression estimate its occurrence in anywhere from 20-80% of cases. Estimates from community samples tend to find lower rates than from specialist centres. Most studies use self-report questionnaires such as the Beck Depression Inventory, which may overinflate scores due to physical symptoms. Studies using diagnostic interviews by trained psychiatrists also report lower rates of depression. More generally, there is an increased risk for any individual with depression to go on to develop Parkinson's disease at a later date. Seventy percent of individuals with Parkinson's disease diagnosed with pre-existing depression go on to develop anxiety. Ninety percent of Parkinson's disease patients with pre-existing anxiety subsequently develop depression; apathy or abulia.
Cognitive disturbances include:
- Slowed reaction time; both voluntary and involuntary motor responses are significantly slowed.
- Executive dysfunction, characterized by difficulties in: differential allocation of attention, impulse control, set shifting, prioritizing, evaluating the salience of ambient data, interpreting social cues, and subjective time awareness. This complex is present to some degree in most Parkinson's patients; it may progress to:
- Dementia: a later development in approximately 20-40% of all patients, typically starting with slowing of thought and progressing to difficulties with abstract thought, memory, and behavioral regulation. Hallucinations, delusions and paranoia may develop.
- Short term memory loss; procedural memory is more impaired than declarative memory. Prompting elicits improved recall.
- Non-motor causes of speech/language disturbance in both expressive and receptive language: these include decreased verbal fluency and cognitive disturbance especially related to comprehension of emotional content of speech and of facial expression.
- Medication effects: some of the above cognitive disturbances are improved by dopaminergic medications, while others are actually worsened.
- Excessive daytime somnolence
- Initial, intermediate, and terminal insomnia
- Disturbances in REM sleep: disturbingly vivid dreams, and REM Sleep Disorder, characterized by acting out of dream content — can occur years prior to diagnosis
- Impaired visual contrast sensitivity, spatial reasoning, colour discrimination, convergence insufficiency (characterized by double vision) and oculomotor control
- Dizziness and fainting; usually attributable orthostatic hypotension, a failure of the autonomic nervous system to adjust blood pressure in response to changes in body position
- Impaired proprioception (the awareness of bodily position in three-dimensional space)
- Reduction or loss of sense of smell (hyposmia or anosmia) - can occur years prior to diagnosis
- pain: neuropathic, muscle, joints, and tendons, attributable to tension, dystonia, rigidity, joint stiffness, and injuries associated with attempts at accommodation
- Oily skin and seborrheic dermatitis
- Urinary incontinence, typically in later disease progression
- Nocturia (getting up in the night to pass urine) — up to 60% of cases
- Constipation and gastric dysmotility that is severe enough to endanger comfort and even health
- Altered sexual function: characterized by profound impairment of sexual arousal, behavior, orgasm, and drive is found in mid and late Parkinson disease. Current data addresses male sexual function almost exclusively.
- Weight loss, which is significant over a period of ten years.
Most people with Parkinson's disease are described as having idiopathic Parkinson's disease (having no specific cause). There are far less common causes of Parkinson's disease including genetic, toxins, head trauma, cerebral anoxia, and drug-induced Parkinson's disease.
In recent years, a number of specific genetic mutations causing Parkinson's disease have been discovered, including in certain populations (Contursi, Italy). These account for a small minority of cases of Parkinson's disease. Someone who has Parkinson's disease is more likely to have relatives that also have Parkinson's disease.However, this does not mean that the disorder has been passed on genetically.
One theory holds that the disease may result in many or even most cases from the combination of a genetically determined vulnerability to environmental toxins along with exposure to those toxins. This hypothesis is consistent with the fact that Parkinson's disease is not distributed homogeneously throughout the population; its incidence varies geographically. However, it is not consistent with the fact that the first appearance of the syndrome predates the first synthesis of the compounds often attributed to causing Parkinson's disease. The toxins most strongly suspected at present are certain pesticides and transition-series metals such as manganese or iron, especially those that generate reactive oxygen species, and/or bind to neuromelanin, as originally suggested by G.C. Cotzias. In the Cancer Prevention Study II Nutrition Cohort, a longitudinal investigation, individuals who were exposed to pesticides had a 70% higher incidence of PD than individuals who were not exposed.
The tragedy of a group of drug addicts in California in the early 1980s who consumed a contaminated and illicitly produced batch of the synthetic opiate MPPP brought to light MPTP (pro-toxin N-methyl-4-phenyl-1,2,3,6-tetrahydropyidine) as a specific cause of Parkinson symptoms. This made it possible to develop the first animal model for Parkinson's. MPTP's toxicity likely comes from the generation of reactive oxygen species through tyrosine hydroxylation. The Case of the Frozen Addicts by J. William Langston (Vintage, New York, June 25, 1996) documents this tragedy and describes the first attempts at fetal brain tissue transplants to treat PD.
Other toxin-based models employ PCBs, paraquat (a herbicide) in combination with maneb (a fungicide), rotenone (an insecticide), and specific organochlorine pesticides including dieldrin and lindane. Rotenone is an inhibitor of complex 1 of the electron transport chain. It easily crosses membranes due to its extremely hydrophobic properties. Rotenone, therefore, does not rely on the dopamine transporter to enter into the cytoplasm. Numerous studies have found an increase in PD in persons who consume rural well water; researchers theorize that water consumption is a proxy measure of pesticide exposure. In agreement with this hypothesis are studies which have found a dose-dependent increase in PD in persons exposed to agricultural chemicals.
Past episodes of head trauma are reported more frequently by individuals with Parkinson's disease than by others in the population. A recent methodologically strong retrospective study found that those who have experienced a head injury are four times more likely to develop Parkinson’s disease than those who have never suffered a head injury. The risk of developing Parkinson’s increases eightfold for patients who have had head trauma requiring hospitalization, and it increases 11-fold for patients who had experienced severe head injury. The authors comment that since head trauma is a rare event, the contribution to PD incidence is slight. They express further concern that their results may be biased by recall, i.e., the PD patients because they reflect upon the causes of their illness, may remember head trauma better than the non-ill control subjects. These limitations were overcome recently by Tanner and colleagues, who found a similar risk of 3.8, with increasing risk associated with more severe injury and hospitalization. However, whether the head trauma actually contributed to Parkinson's disease development or the early symptoms of clumsiness associated with Parkinson's causes individuals to have more head trauma is still unknown.
The symptoms of Parkinson's disease result from the loss of pigmented dopamine-secreting (dopaminergic) cells in the pars compacta region of the substantia nigra (literally "black substance"). These neurons project to the striatum and their loss leads to alterations in the activity of the neural circuits within the basal ganglia that regulate movement, in essence an inhibition of the direct pathway and excitation of the indirect pathway.
The direct pathway facilitates movement and the indirect pathway inhibits movement, thus the loss of these cells leads to a hypokinetic movement disorder. The lack of dopamine results in increased inhibition of the ventral anterior nucleus of the thalamus, which sends excitatory projections to the motor cortex, thus leading to hypokinesia.
There are four major dopamine pathways in the brain; the nigrostriatal pathway, referred to above, mediates movement and is the most conspicuously affected in early Parkinson's disease. The other pathways are the mesocortical, the mesolimbic, and the tuberoinfundibular. Disruption of dopamine along the non-striatal pathways likely explains much of the neuropsychiatric pathology associated with Parkinson's disease.
The mechanism by which the brain cells in Parkinson's are lost may consist of an abnormal accumulation of the protein alpha-synuclein bound to ubiquitin in the damaged cells. The alpha-synuclein-ubiquitin complex cannot be directed to the proteosome. This protein accumulation forms proteinaceous cytoplasmic inclusions called Lewy bodies. The latest research on pathogenesis of disease has shown that the death of dopaminergic neurons by alpha-synuclein is due to a defect in the machinery that transports proteins between two major cellular organelles — the endoplasmic reticulum (ER) and the Golgi apparatus. Certain proteins like Rab1 may reverse this defect caused by alpha-synuclein in animal models.
Excessive accumulations of iron, which are toxic to nerve cells, are also typically observed in conjunction with the protein inclusions. Iron and other transition metals such as copper bind to neuromelanin in the affected neurons of the substantia nigra. Neuromelanin may be acting as a protective agent. The most likely mechanism is generation of reactive oxygen species. Iron also induces aggregation of synuclein by oxidative mechanisms. Similarly, dopamine and the byproducts of dopamine production enhance alpha-synuclein aggregation. The precise mechanism whereby such aggregates of alpha-synuclein damage the cells is not known. The aggregates may be merely a normal reaction by the cells as part of their effort to correct a different, as-yet unknown, insult. Based on this mechanistic hypothesis, a transgenic mouse model of Parkinson's has been generated by introduction of human wild-type alpha-synuclein into the mouse genome under control of the platelet-derived-growth factor-β promoter.
Typically, the diagnosis is based on medical history and neurological examination conducted by interviewing and observing the patient in person using the Unified Parkinson's Disease Rating Scale. A radiotracer for SPECT scanning machines called DaTSCAN and made by General Electric is specialized for diagnosing Parkinson's Disease, but it is only marketed in Europe. Due to this, the disease can be difficult to diagnose accurately, especially in its early stages. Due to symptom overlap with other diseases, only 75% of clinical diagnoses of PD are confirmed to be idiopathic PD at autopsy. Early signs and symptoms of PD may sometimes be dismissed as the effects of normal aging. The physician may need to observe the person for some time until it is apparent that the symptoms are consistently present. Usually doctors look for shuffling of feet and lack of swing in the arms. Doctors may sometimes request brain scans or laboratory tests in order to rule out other diseases. However, CT and MRI brain scans of people with PD usually appear normal.
Clinical practice guidelines introduced in the UK in 2006 state that the diagnosis and follow-up of Parkinson's disease should be done by a specialist in the disease, usually a neurologist or geriatrician with an interest in movement disorders.
Parkinson's disease is a chronic disorder that requires broad-based management including patient and family education, support group services, general wellness maintenance, physiotherapy, exercise, and nutrition. At present, there is no cure for PD, but medications or surgery can provide relief from the symptoms.
The most widely used form of treatment is L-dopa in various forms. L-dopa is transformed into dopamine in the dopaminergic neurons by L-aromatic amino acid decarboxylase (often known by its former name dopa-decarboxylase). However, only 1-5% of L-DOPA enters the dopaminergic neurons. The remaining L-DOPA is often metabolised to dopamine elsewhere, causing a wide variety of side effects. Due to feedback inhibition, L-dopa results in a reduction in the endogenous formation of L-dopa, and so eventually becomes counterproductive.
Carbidopa and benserazide are dopa decarboxylase inhibitors. They help to prevent the metabolism of L-dopa before it reaches the dopaminergic neurons and are generally given as combination preparations of carbidopa/levodopa (co-careldopa) (e.g. Sinemet, Parcopa) and benserazide/levodopa (co-beneldopa) (e.g. Madopar). There are also controlled release versions of Sinemet and Madopar that spread out the effect of the L-dopa. Duodopa is a combination of levodopa and carbidopa, dispersed as a viscous gel. Using a patient-operated portable pump, the drug is continuously delivered via a tube directly into the upper small intestine, where it is rapidly absorbed. There is also Stalevo (Carbidopa, Levodopa and Entacapone).
Tolcapone inhibits the COMT enzyme, thereby prolonging the effects of L-dopa, and so has been used to complement L-dopa. However, due to its possible side effects such as liver failure, it's limited in its availability. A similar drug, entacapone has not been shown to cause significant alterations of liver function and maintains adequate inhibition of COMT over time.
The dopamine agonists bromocriptine, pergolide, pramipexole, ropinirole , cabergoline, apomorphine, and lisuride are moderately effective. These have their own side effects including those listed above in addition to somnolence, hallucinations and/or insomnia. Several forms of dopamine agonism have been linked with a markedly increased risk of problem gambling. Dopamine agonists initially act by stimulating some of the dopamine receptors. However, they cause the dopamine receptors to become progressively less sensitive, thereby eventually increasing the symptoms.
Dopamine agonists can be useful for patients experiencing on-off fluctuations and dyskinesias as a result of high doses of L-dopa. Apomorphine can be administered via subcutaneous injection using a small pump which is carried by the patient. A low dose is automatically administered throughout the day, reducing the fluctuations of motor symptoms by providing a steady dose of dopaminergic stimulation. After an initial "apomorphine challenge" in hospital to test its effectiveness and brief patient and primary caregiver (often a spouse or partner), the latter of whom takes over maintenance of the pump. The injection site must be changed daily and rotated around the body to avoid the formation of nodules. Apomorphine is also available in a more acute dose as an autoinjector pen for emergency doses such as after a fall or first thing in the morning. Nausea and vomiting are common, and may require domperidone (an antiemetic).
Selegiline and rasagiline reduce the symptoms by inhibiting monoamine oxidase-B (MAO-B), which inhibits the breakdown of dopamine secreted by the dopaminergic neurons. Metabolites of selegiline include L-amphetamine and L-methamphetamine (not to be confused with the more notorious and potent dextrorotary isomers). This might result in side effects such as insomnia. Use of L-dopa in conjunction with selegiline has increased mortality rates that have not been effectively explained. Another side effect of the combination can be stomatitis. One report raised concern about increased mortality when MAO-B inhibitors were combined with L-dopa; however subsequent studies have not confirmed this finding. Unlike other non selective monoamine oxidase inhibitors, tyramine-containing foods do not cause a hypertensive crisis.
Surgery and deep brain stimulation
Treating Parkinson's disease with surgery was once a common practice, but after the discovery of levodopa, surgery was restricted to only a few cases. Studies in the past few decades have led to great improvements in surgical techniques, and surgery is again being used in people with advanced PD for whom drug therapy is no longer sufficient.
Deep brain stimulation is presently the most used surgical means of treatment, but other surgical therapies that have shown promise include surgical lesion of the subthalamic nucleus and of the internal segment of the globus pallidus, a procedure known as pallidotomy.
There is partial evidence that speech or mobility problems can improve with rehabilitation although studies are still scarce and of low quality. Regular physical exercise and/or therapy can be beneficial to the patient for maintaining and improving mobility, flexibility, strength, gait speed, and quality of life; and speech therapy may improve voice and speech function. One of the most widely practiced treatment for the speech disorders associated with Parkinson's disease is the Lee Silverman Voice Treatment (LSVT). LSVT focuses on increasing vocal loudness.
PD is not considered to be a fatal disease by itself, but it progresses with time. The average life expectancy of a PD patient is generally lower than for people who do not have the disease. In the late stages of the disease, PD may cause complications such as choking, pneumonia, and falls that can lead to death.
The progression of symptoms in PD may take 20 years or more. In some people, however, the disease progresses more quickly. There is no way to predict what course the disease will take for an individual person. With appropriate treatment, most people with PD can live productive lives for many years after diagnosis.
In at least some studies, it has been observed that mortality was significantly increased, and longevity decreased among nursing home patients as compared to community dwelling patients.
One commonly used system for describing how the symptoms of PD progress is called the Hoehn and Yahr scale. Another commonly used scale is the Unified Parkinson's Disease Rating Scale (UPDRS). This much more complicated scale has multiple ratings that measure motor function, and also mental functioning, behavior, mood, and activities of daily living. Both the Hoehn and Yahr scale and the UPDRS are used to measure how individuals are faring and how much treatments are helping them. It should be noted that neither scale is specific to Parkinson's disease; that patients with other illnesses can score in the Parkinson's range.
According to some sources, Parkinsons disease is slightly less prevalent in the African-American community. The average crude prevalence is estimated at being from 120-180 out of 100,000 among the Caucasian (white) community. The Parsi community in Mumbai, India suffers from particularly high rates of Parkinson's disease.
Symptoms of Parkinson's disease have been known and treated since medieval times, most notably by Averroes. However, it was not formally recognized and its symptoms were not documented until 1817 in An Essay on the Shaking Palsy by the British physician James Parkinson. Parkinson's disease was then known as paralysis agitans, the term "Parkinson's disease" being coined later by Jean-Martin Charcot. The underlying biochemical changes in the brain were identified in the 1950s due largely to the work of Swedish scientist Arvid Carlsson, who later went on to win a Nobel Prize. L-dopa entered clinical practice in 1967, and the first large study reporting improvements in patients with Parkinson's disease resulting from treatment with L-dopa was published in 1968.
Currently under investigation is gene therapy. This involves using a non-infectious virus to shuttle a gene into a part of the brain called the subthalamic nucleus (STN). The gene used leads to the production of an enzyme called glutamic acid decarboxylase (GAD), which catalyses the production of a neurotransmitter called GABA. GABA acts as a direct inhibitor on the overactive cells in the STN.
GDNF infusion involves the infusion of GDNF (glial-derived neurotrophic factor) into the basal ganglia using surgically implanted catheters. Via a series of biochemical reactions, GDNF stimulates the formation of L-dopa. GDNF therapy is still in development.
Implantation of stem cells genetically engineered to produce dopamine or stem cells that transform into dopamine-producing cells has already started being used. These could not constitute cures because they do not address the considerable loss of activity of the dopaminergic neurons. Initial results have been unsatisfactory, with patients still retaining their drugs and symptoms.
Neuroprotective treatments are at the forefront of PD research, but are still under clinical scrutiny. These agents could protect neurons from cell death induced by disease presence resulting in a slower progression of disease. Agents currently under investigation as neuroprotective agents include anti-apoptotic drugs (CEP 1347 and CTCT346), lazaroids, bioenergetics, antiglutamatergic agents and dopamine receptors. Clinically evaluated neuroprotective agents are the monoamine oxidase inhibitors selegiline and rasagiline, dopamine agonists, and the complex I mitochondrial fortifier coenzyme Q10.
The first prospective randomised double-blind sham-placebo controlled trial of dopamine-producing cell transplants failed to show an improvement in quality of life although some significant clinical improvements were seen in patients below the age of 60. A significant problem was the excess release of dopamine by the transplanted tissue, leading to dystonias. Research in African green monkeys suggests that the use of stem cells might in future provide a similar benefit without inducing dystonias.
Nutrients have been used in clinical studies and are used by people with PD in order to partially treat PD or slow down its deterioration. The L-dopa precursor L-tyrosine was shown to relieve an average of 70% of symptoms. Ferrous iron, the essential cofactor for L-dopa biosynthesis was shown to relieve between 10% and 60% of symptoms in 110 out of 110 patients.  More limited efficacy has been obtained with the use of THFA, NADH, and pyridoxine—coenzymes and coenzyme precursors involved in dopamine biosynthesis. Vitamin C and vitamin E in large doses are commonly used by patients in order to theoretically lessen the cell damage that occurs in PD. This is because the enzymes superoxide dismutase and catalase require these vitamins in order to nullify the superoxide anion, a toxin commonly produced in damaged cells. However, in the randomized controlled trial, DATATOP of patients with early PD, no beneficial effect for vitamin E compared to placebo was seen. Coenzyme Q10 has more recently been used for similar reasons. MitoQ is a newly developed synthetic substance that is similar in structure and function to coenzyme Q10.
- ↑ 1.0 1.1 1.2 Jankovic J (April 2008). Parkinson's disease: clinical features and diagnosis. J. Neurol. Neurosurg. Psychiatr. 79 (4): 368–76.
- ↑ 2.0 2.1 2.2 Template:NICE
- ↑ Lepoutre A, Devos D, Blanchard-Dauphin A, et al (2006). A specific clinical pattern of camptocormia in Parkinson's disease. J. Neurol. Neurosurg. Psychiatr. 77 (11): 1229–34.
- ↑ Fox, Michael (2003). Lucky Man: A Memoir, 214, Hyperion.
- ↑ Deuschl G, Goddemeier C (1998). Spontaneous and reflex activity of facial muscles in dystonia, Parkinson's disease, and in normal subjects. J. Neurol. Neurosurg. Psychiatr. 64 (3): 320–4.
- ↑ Lieberman A (2006). Depression in Parkinson's disease -- a review. Acta Neurol Scand 113 (1): 1–8.
- ↑ Ishihara L, Brayne C (2006). A systematic review of depression and mental illness preceding Parkinson's disease. Acta Neurol Scand 113 (4): 211–20.
- ↑ Pell M (1996). On the receptive prosodic loss in Parkinson's disease. Cortex 32 (4): 693–704.
- ↑ Frank MJ (2005). Dynamic dopamine modulation in the basal ganglia: a neurocomputational account of cognitive deficits in medicated and nonmedicated Parkinsonism. Journal of cognitive neuroscience 17 (1): 51–72.
- ↑ Gupta A, Bluhm R (2004). Seborrheic dermatitis. Journal of the European Academy of Dermatology and Venereology : JEADV 18 (1): 13–26; quiz 19–20.
- ↑ Di Monte DA, Lavasani M, Manning-Bog AB (2002). Environmental factors in Parkinson's disease. Neurotoxicology 23 (4-5): 487–502.
- ↑ 12.0 12.1 Jenner P (1998). Oxidative mechanisms in nigral cell death in Parkinson's disease. Mov. Disord. 13 Suppl 1: 24–34.
- ↑ Chiueh CC, Andoh T, Lai AR, Lai E, Krishna G (2000). Neuroprotective strategies in Parkinson's disease: protection against progressive nigral damage induced by free radicals. Neurotoxicity research 2 (2-3): 293–310.
- ↑ Cotzias G (1966). Manganese, melanins and the extrapyramidal system. J Neurosurg 24 (1): Suppl:170–80.
- ↑ Barbeau A (1984). Manganese and extrapyramidal disorders (a critical review and tribute to Dr. George C. Cotzias). Neurotoxicology 5 (1): 13–35.
- ↑ Ascherio A, Chen H, Weisskopf M, et al (2006). Pesticide exposure and risk for Parkinson's disease. Ann Neurol 60 (2): 197–203.
- ↑ Chiueh C, Wu R, Mohanakumar K, Sternberger L, Krishna G, Obata T, Murphy D (1994). In vivo generation of hydroxyl radicals and MPTP-induced dopaminergic toxicity in the basal ganglia. Ann N Y Acad Sci 738: 25–36.
- ↑ includeonly>Orr, Leslie. "PCBs, fungicide open brain cells to Parkinson's assault", Medical News Today, February 10, 2005.
- ↑ Manning-Bog AB, McCormack AL, Li J, Uversky VN, Fink AL, Di Monte DA (2002). The herbicide paraquat causes up-regulation and aggregation of alpha-synuclein in mice: paraquat and alpha-synuclein. J. Biol. Chem. 277 (3): 1641–4.
- ↑ Thiruchelvam M, Richfield EK, Baggs RB, Tank AW, Cory-Slechta DA (2000). The nigrostriatal dopaminergic system as a preferential target of repeated exposures to combined paraquat and maneb: implications for Parkinson's disease. J. Neurosci. 20 (24): 9207–14.
- ↑ Betarbet R, Sherer TB, MacKenzie G, Garcia-Osuna M, Panov AV, Greenamyre JT (2000). Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nat. Neurosci. 3 (12): 1301–6.
- ↑ Kitazawa M, Anantharam V, Kanthasamy AG (2001). Dieldrin-induced oxidative stress and neurochemical changes contribute to apoptopic cell death in dopaminergic cells. Free Radic. Biol. Med. 31 (11): 1473–85.
- ↑ Corrigan FM, Wienburg CL, Shore RF, Daniel SE, Mann D (2000). Organochlorine insecticides in substantia nigra in Parkinson's disease. J. Toxicol. Environ. Health Part A 59 (4): 229–34.
- ↑ 24.0 24.1 Bower JH, Maraganore DM, Peterson BJ, McDonnell SK, Ahlskog JE, Rocca WA (2003). Head trauma preceding PD: a case-control study. Neurology 60 (10): 1610–5.
- ↑ Stern M, Dulaney E, Gruber SB, et al (1991). The epidemiology of Parkinson's disease. A case-control study of young-onset and old-onset patients. Arch. Neurol. 48 (9): 903–7.
- ↑ Uryu K, Giasson BI, Longhi L, et al (2003). Age-dependent synuclein pathology following traumatic brain injury in mice. Exp. Neurol. 184 (1): 214–24.
- ↑ Goldman SM, Tanner CM, Oakes D, Bhudhikanok GS, Gupta A, Langston JW (2006). Head injury and Parkinson's disease risk in twins. Ann. Neurol. 60 (1): 65–72.
- ↑ "Parkinson's Disease Mechanism Discovered," HHMI Research News June 22, 2006.
- ↑ Kaur D, Andersen J (2002). Ironing out Parkinson's disease: is therapeutic treatment with iron chelators a real possibility?. Aging Cell 1 (1): 17–21.
- ↑ Masliah E, Rockenstein E, Veinbergs I, et al (2000). Dopaminergic loss and inclusion body formation in alpha-synuclein mice: implications for neurodegenerative disorders. Science 287 (5456): 1265–9.
- ↑ Gelb D, Oliver E, Gilman S (1999). Diagnostic criteria for Parkinson disease. Arch Neurol 56 (1): 33–9.
- ↑ R. Cilia et al. (2006). Long-term Efficacy of Entacapone in Patients with Parkinson's Disease and Motor Fluctuations - A Six-Year Clinical Follow-Up Study.
- ↑ Thorogood M, Armstrong B, Nichols T, Hollowell J (1998). Mortality in people taking selegiline: observational study. BMJ 317 (7153): 252–4.
- ↑ Marras C, McDermott M, Rochon P, Tanner C, Naglie G, Rudolph A, Lang A (2005). Survival in Parkinson disease: thirteen-year follow-up of the DATATOP cohort. Neurology 64 (1): 87–93.
- ↑ Guridi J, Obeso JA (2001). The subthalamic nucleus, hemiballismus and Parkinson's disease: reappraisal of a neurosurgical dogma. Brain 124 (Pt 1): 5–19.
- ↑ Fukuda M, Kameyama S, Yoshino M, Tanaka R, Narabayashi H (2000). Neuropsychological outcome following pallidotomy and thalamotomy for Parkinson's disease. Stereotactic and functional neurosurgery 74 (1): 11–20.
- ↑ Deane KH, Jones D, Playford ED, Ben-Shlomo Y, Clarke CE (2001). Physiotherapy for patients with Parkinson's Disease: a comparison of techniques. Cochrane Database Syst Rev (3): CD002817.
- ↑ Deane KH, Whurr R, Playford ED, Ben-Shlomo Y, Clarke CE (2001). A comparison of speech and language therapy techniques for dysarthria in Parkinson's disease. Cochrane Database Syst Rev (2): CD002814.
- ↑ 39.0 39.1 Goodwin VA, Richards SH, Taylor RS, Taylor AH, Campbell JL (April 2008). The effectiveness of exercise interventions for people with Parkinson's disease: a systematic review and meta-analysis. Mov. Disord. 23 (5): 631–40.
- ↑ 40.0 40.1 Schulz GM (July 2002). The effects of speech therapy and pharmacological treatments on voice and speech in Parkinson s disease: a review of the literature. Curr. Med. Chem. 9 (14): 1359–66.
- ↑ Fox CM, Ramig LO, Ciucci MR, Sapir S, McFarland DH, Farley BG (November 2006). The science and practice of LSVT/LOUD: neural plasticity-principled approach to treating individuals with Parkinson disease and other neurological disorders. Semin Speech Lang 27 (4): 283–99.
- ↑ Parkinson's Disease. Mayo Clinic: College of Medicine. URL accessed on 2006-11-04.
- ↑ Goetz CG, Stebbins GT (1995). Mortality and hallucinations in nursing home patients with advanced Parkinson's disease. Neurology 45 (4): 669–71.
- ↑ http://holisticonline.com/Remedies/Parkinson/pd_who-gets.htm
- ↑ http://archneur.ama-assn.org/cgi/content/abstract/45/12/1321
- ↑ http://holisticonline.com/Remedies/Parkinson/pd_who-gets.htm
- ↑ Manyam BV, Sánchez-Ramos JR (1999). Traditional and complementary therapies in Parkinson's disease. Advances in neurology 80: 565–74.
- ↑ Parkinson J (2002). An essay on the shaking palsy. 1817. J Neuropsychiatry Clin Neurosci 14 (2): 223–36; discussion 222.
- ↑ Hornykiewicz O (2002). L-DOPA: from a biologically inactive amino acid to a successful therapeutic agent. Amino Acids 23 (1-3): 65–70.
- ↑ Cotzias G (1968). L-Dopa for Parkinsonism. N Engl J Med 278 (11): 630.
- ↑ Kaplitt MG, Feigin A, Tang C, Fitzsimons HL, Mattis P, Lawlor PA, Bland RJ, Young D, Strybing K, Eidelberg D, During MJ (2007). Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson's disease: an open label, phase I trial. Lancet 369 (9579): 2097–105.
- ↑ Bonuccelli U, Del Dotto P (2006). New pharmacologic horizons in the treatment of Parkinson disease. Neurology 67 (2): 30–38.
- ↑ Djaldetti R, Melamed E (2002). New drugs in the future treatment of Parkinson's disease. J. Neurol. 249 Suppl 2: II30–5.
- ↑ 54.0 54.1 (1993) Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. The Parkinson Study Group. N. Engl. J. Med. 328 (3): 176–83.
- ↑ Freed CR, Greene PE, Breeze RE, et al (2001). Transplantation of embryonic dopamine neurons for severe Parkinson's disease. N. Engl. J. Med. 344 (10): 710–9.
- ↑ Redmond DE (2002). Cellular replacement therapy for Parkinson's disease--where we are today?. The Neuroscientist : a review journal bringing neurobiology, neurology and psychiatry 8 (5): 457–88.
- ↑ Redmond E et al (2007). Behavioral improvement in a primate Parkinson's model is associated with multiple homeostatic effects of human neural stem cells. Proceedings of the National Academy of Sciences 104 (29): 12175.
- ↑ Lemoine P, Robelin N, Sebert P, Mouret J (1986). La L-tyrosine : traitement au long cours de la maladie de Parkinson [L-tyrosine : A long term treatment of Parkinson's Disease]. Comptes rendus academie des sciences 309: 43–47.
- ↑ Birkmayer W, Birkmayer JG (1986). Iron, a new aid in the treatment of Parkinson patients. J. Neural Transm. 67 (3-4): 287–92.
- ↑ (1989) Editors Przuntek H , Riederer P Early diagnosis and preventive therapy in Parkinson's disease, p. 323, Springer.
- ↑ Dopamine biosynthesis. (Word doc) University of Chicago Personal Web Pages. URL accessed on 2006-11-04.
- ↑ Schmitz-Hubsch T (2006). Qigong exercise for the symptoms of Parkinson's disease: a randomized, controlled pilot study. Mov Disord 21 (4): 543–548.
- ↑ Burini D, Farabollini B, Iacucci S, et al (2006). A randomised controlled cross-over trial of aerobic training versus qigong in advanced Parkinson's disease. Europa medicophysica 42 (3): 231–8.
- ↑ Katzenschlager R, Evans A, Manson A, et al (2004). Mucuna pruriens in Parkinson's disease: a double blind clinical and pharmacological study. J. Neurol. Neurosurg. Psychiatr. 75 (12): 1672–7.
- Parkinson's Disease at the Open Directory Project
- Parkinson's Disease: Hope Through Research (National Institute of Neurological Disorders and Stroke)
- World Parkinson Disease Association
|This page uses Creative Commons Licensed content from Wikipedia (view authors).|